Shingles clinical trials

Explore recruiting shingles clinical trials.

Recruiting shingles studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Shingles trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Characterization of the immune response in immunosuppressed patients with rheumatic diseases, including to the recombinant zoster vaccine

France

Therapeutic use (Phase IV) EU CTIS Study details

Immune response to the recombinant Zoster Vaccine in people living with HIV over 50 years of age compared to non-HIV age- and gender-matched controls - Shingr'HIV

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Shingles trials by city

Shingles in Toronto Shingles in Vancouver Shingles in Montreal Shingles in Calgary Shingles in Edmonton Shingles in Ottawa Shingles in Winnipeg Shingles in Quebec City Shingles in Hamilton Shingles in Kitchener Shingles in London Shingles in Halifax Shingles in New York Shingles in Los Angeles Shingles in Chicago Shingles in Houston

Shingles clinical trials

Recruiting shingles studies right now

Subcutaneous Calcitonin in Acute Herpes Zoster

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland

Effect of MTX Discontinuation on Shingrix Response in RA

Safety of the Herpes Zoster Subunit Vaccine in Lupus

Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine

Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population

Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older

Esketamine Combined Pulsed Radiofrequency for Acute/Subacute Zoster-associated Trigeminal Neuralgia

Shingrix in Renal Transplant Recipients

Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators

A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine

Also recruiting in Europe

Characterization of the immune response in immunosuppressed patients with rheumatic diseases, including to the recombinant zoster vaccine

Immune response to the recombinant Zoster Vaccine in people living with HIV over 50 years of age compared to non-HIV age- and gender-matched controls - Shingr'HIV

Shingles trials by city

Other conditions